Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9J19
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,119
Award facts
- Contract value 100% obligated
- $17,118.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $17,118.96. This competitively awarded, firm fixed-price delivery order was executed on November 24, 2025, with an ultimate completion date of November 25, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic treatment for moderate-to-severe atopic dermatitis, atopic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic conditions, making this a critical pharmaceutical supply for military and federal healthcare beneficiaries.
This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. That prime contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's extensive portfolio of federal medical product deliveries demonstrates its established capability as a primary pharmaceutical distributor for the Defense Health Agency and other government healthcare systems. The company's consistent receipt of competitively awarded contracts across multiple therapeutic domains underscores its pivotal role within the federal medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F9J19?
SPE2DR26F9J19 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26F9J19 worth?
The government has obligated $17,119 on SPE2DR26F9J19.
Is contract SPE2DR26F9J19 an order under another contract?
Yes. SPE2DR26F9J19 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9J19 competed?
The extent of competition for SPE2DR26F9J19 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award